Compositions and kits for diagnosing and prognosing Alzheimer's
Disease (AD) in a
human patient include a binding agent such as a
monoclonal antibody for a biomarker conjugated to a detectable
moiety such as a
fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other
phagocytosis-related molecules. Further compositions and kits employ panels of
fluorophore-conjugated
monoclonal antibodies for biomarkers including
scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the
efficacy of AD therapeutic candidates such as
phagocytosis-promoting agents and
scavenger receptor agonists also appear.